MADISON, Wis.--(BUSINESS WIRE)--Exact Sciences (Nasdaq: EXAS) today presented data showing that its non-invasive CologuardTM stool-based (sDNA) screening test detected 64 percent of colorectal pre-cancers and 85 percent of cancers. The study was conducted in collaboration with Mayo Clinic and examined more than 1,100 patient samples. Results were presented at the 2010 Special Conference for Colorectal Cancer: Biology to Therapy held by the American Association for Cancer Research in Philadelphia, PA.
